Private TB Drug Markets in High Burden Countries
Author Information
Author(s): William A. Wells, Colin Fan, Nitin Patel, Teresa Oh, Elizabeth Gardiner, Michael E. Kimerling
Primary Institution: Global Alliance for TB Drug Development
Hypothesis
What are the characteristics and sizes of private sector TB drug markets in high burden countries?
Conclusion
Private TB drug markets in several high burden countries are substantial and complex, necessitating policy responses.
Supporting Evidence
- Private TB drug markets in four countries had the largest sales volumes.
- First line drug volumes were predominantly fixed dose combinations in five countries.
- There were 54 distinct first line manufacturers across the ten countries.
Takeaway
This study looks at how many TB drugs are sold in private markets in countries where TB is a big problem, showing that these markets are important and need better rules.
Methodology
The study analyzed IMS Health data on private TB drug consumption in 10 high burden countries.
Potential Biases
Potential bias due to incomplete data coverage in lower-income markets.
Limitations
The study relies on IMS data, which may not cover all private market channels and could underestimate drug volumes.
Participant Demographics
The study focuses on 10 high burden countries with significant TB incidence.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website